Is CBD legal in Japan?

Legal status

CBD is not a controlled substance in Japan. Cannabidiol is not named in 別表第一, in the Cabinet Order's narcotics or psychotropics articles, in the 覚醒剤取締法 or in the designated substances ordinance, and the ordinance's three dibenzopyran group clauses, 省令第一条第三百六十三号 to 第三百六十五号, do not reach it because each requires the closed dibenzopyran ring system that CBD, a ring opened cannabinoid, does not have. A mechanical search of the control lists and the MHLW and Narcotics Control Department list PDFs on 2 October 2026 for カンナビジオール, cannabidiol and CBD found none of those terms. That absence is stated as at the narcotics tables status 6 September 2026, the psychotropics tables status 3 October 2025 and the designated substances list status 6 September 2026. What controls a CBD product is its delta 9 THC content. Delta 9 THC is a 麻薬 at 別表第一第四十二号, and 第七十八号ロ excludes from the narcotics only 「その濫用による保健衛生上の危害が発生しない量として政令で定める量以下の第四十二号に掲げる物（大麻草としての形状を有しないものに限る。）を含有する物であつて、前各号（同号を除く。）に掲げる物又は大麻を含有しないもの」. In plain terms the exclusion needs three things: the delta 9 THC is not in the shape of the plant, it is at or below the limit, and the product contains no other substance in 別表第一 and no cannabis. The Cabinet Order's 第二条 fixes the limit as: oils that are liquid at room temperature and powders, 「油脂（常温において液体であるものに限る。）及び粉末百万分中十分の量」 (10 ppm); aqueous solutions, 「水溶液一億分中十分の量」 (0.1 ppm); and everything else, 「前二号に掲げる物以外のもの百万分中一分の量」 (1 ppm). A product above its limit is a 麻薬, and the MHLW cannabis reform page says so in terms: «この値を超える量のΔ9-THCを含有する製品等は「麻薬」に該当します。» A second rule now applies too: cannabinol became a designated substance on 1 June 2026, so a CBD product that contains CBN is a 指定薬物 product whatever its THC content. The Cabinet Order's 第六条 also deems two tetrahydrocannabinolic acids, for example 「六ａ・七・八・十ａ―テトラヒドロ―一―ヒドロキシ―六・六・九―トリメチル―三―ペンチル―六Ｈ―ジベンゾ［ｂ・ｄ］ピラン―二―カルボン酸及びその塩類」, to be narcotics under 第二条第二項; the instruments read do not say how that applies to traces of THCA in a CBD product, so such traces are a further risk this cell does not resolve.

Consequences if caught

Capital exposure: none. No Japanese drug statute provides a death sentence: 死刑 appears in the main provisions of none of the 麻薬及び向精神薬取締法 (the Narcotics and Psychotropics Control Act), the 覚醒剤取締法 (the Stimulants Control Act), the あへん法 (the Opium Act), the 大麻草の栽培の規制に関する法律 (the Cannabis Plant Cultivation Act), the pharmaceuticals Act (the PMD Act) or the 麻薬特例法 (the Narcotics Special Provisions Act), each read on e-Gov on 2 October 2026. Japan has not abolished capital punishment: 刑法第九条 lists it among the principal punishments, 「死刑、拘禁刑、罰金、拘留及び科料を主刑とし、没収を付加刑とする。」, and 第百九十九条 provides it for murder. Every penalty below reads 拘禁刑, the single form of imprisonment that replaced 懲役 and 禁錮 on the day described in the ministerial ordinance's own words as 「刑法等の一部を改正する法律の施行の日（令和七年六月一日）」, 1 June 2025; under 刑法第十二条第一項 「有期拘禁刑は、一月以上二十年以下とする。」, so an open ended fixed term such as one year or more runs to twenty years, and 第十四条第二項 allows an aggravated fixed term to rise to thirty. The drug statutes took the new term from 令和四年法律第六十八号. Life imprisonment appears in the drug statutes in three places only: 麻薬及び向精神薬取締法第六十四条第二項 (heroin imported, exported or made for profit), 覚醒剤取締法第四十一条第二項 (stimulants imported, exported or made for profit) and 麻薬特例法第五条 (dealing in any 規制薬物 as a business). A CBD product whose delta 9 THC is at or below its limit and not in the shape of the plant, which contains no other substance in 別表第一 and no cannabis (the condition in 第七十八号ロ), and which is free of CBN, carries no drug penalty. A product over the limit is a 麻薬 and takes the ordinary narcotics articles: importing it is 第六十五条第一項第一号, one to ten years; possessing it is 第六十六条第一項, up to seven years; using it is 第六十六条の二, up to seven years, all as 拘禁刑. A product containing CBN falls under the pharmaceuticals Act's 第七十六条の四, with up to three years or a fine of up to three million yen or both for possession or use (第八十四条第二十八号) and up to five years or five million yen or both for dealing as a business (第八十三条の九). The importer carries the risk of the measurement, because the offence turns on the content, not on the label.

If prescribed or medical

CBD has no prescription route because it needs none: a compliant product is not a controlled medicine. There is no approved CBD medicine route set out in the instruments read for this cell; the MHLW reform page describes a clinical research route for patients with intractable epilepsy, which is a study arrangement, not a prescription. For CBN, the MHLW drug abuse page says patients with an intractable condition can continue to use a CBN product through a prescribed procedure: «他に代替できる治療法がない難治性の疾患又は障害の診断を受け、ＣＢＮを含む製品を使用する必要性がある方（以下「患者」といいます。）は、所定の手続きを経ることで、医療等の用途として継続的に使用することができます。»

Documentation

A foreign prescription is irrelevant to a CBD product; what decides whether it can be brought in is its delta 9 THC content measured against the three limits, and whether it contains CBN. The Narcotics Control Department offers a voluntary pre-clearance check and says «この事前確認手続きは、当該製品の輸入に際して必ず必要な法定事項ではありません。» On CBN it says «令和８年６月１日（月）より指定薬物に指定され、CBNを含有する製品（以下「CBN製品」といいます。）の製造、輸入、販売、所持、使用等が禁止されます。» Other product and import law still applies to a compliant product, including the general personal import rule if it is presented as a medicine and food law if it is presented as a food. Tables relied on: the MHLW designation tables, narcotics tables status 6 September 2026 (麻薬の指定状況 令和８年９月６日現在: the Act's 別表第一 with 76 substances and the Cabinet Order's 第一条 with 171, counts that match the e-Gov text read on 2 October 2026); the MHLW designated substances list status 6 September 2026 (the English list headed as of September 6, 2026, 2,484 substances; the Japanese index dates its own copy 令和８年８月27日現在 and gives the same total); and for the absence of CBD itself also the MHLW designation tables, psychotropics tables status 3 October 2025 (向精神薬の指定状況 令和７年10月３日現在: the Act's 別表第三 with 10 substances and the Cabinet Order's 第四条 with 80, counts that match the e-Gov text read on 2 October 2026).

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Japan’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.